Compugen Announced Encouraging News from Its Phase 1/2 Study of COM701
Compugen (CGEN) announced that the first patient has been dosed in the Phase 1/2 study of the triple combination of COM701 - Compugen’s first-in-class anti-PVRIG antibody, with Bristol Myers Squibb’s  (This content is for paid subscribers.